Karen Liu
Founding Partner @ 3E Bioventures
San Francisco Bay Area, United States
Karen Liu is a Series A investor at 3E Bioventures in San Francisco Bay Area focused on Biotechnology and Health Care. Karen Liu is the PartnerPartner at 3E Bioventures Capital . He attended Harvard University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Karen Liu invests in
Stages Karen Liu invests in
Countries Karen Liu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (56%)
- Health Care 4 (44%)
- Wellness 2 (22%)
- Biopharma 2 (22%)
- Pharmaceutical 2 (22%)
Stage
- Series A 4 (44%)
- Series C 2 (22%)
- Series B 1 (11%)
Country
- United States 5 (56%)
- China 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M / Series A / Sep 04, 2025 | ||
| Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $28M / Series A / Jun 20, 2024 | ||
| Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The proprietary technology now owned by Dermaliq, called hyliQ™, is designed to allow cutaneous drug delivery with bioavailability. The technology enables the developmentof effective liquid drug products with exceptional cosmetic properties. | $15M / Series A / Jan 18, 2022 | ||
| ITabMed is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is registered in Lin Gang Sci-Tech City, Shanghai. It was a spin-off entity from the former “Generon BioMed Ltd.”. The company is focused on immunotherapy drug research and development to treat cancer. | $20M / Series A / Dec 01, 2021 | ||
| Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners cangenerate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog. | $6.5M / Series A / Jan 12, 2021 | ||
| Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previouslyinaccessible disease mechanisms.Apexigen pioneers a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms. | $65M / Series C / Mar 24, 2020 | ||
| Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is basedin Cupertino, California. | $45M / Series C / Aug 14, 2018 | ||
| Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previouslyinaccessible disease mechanisms.Apexigen pioneers a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms. | $58M / Series C / Aug 08, 2018 | ||
| Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is basedin Cupertino, California. | $13.2M / Series B / Dec 16, 2015 |
Co-Investors
About 3E Bioventures
3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground Chinaexperiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.
3E Bioventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Karen Liu
Founding Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Karen Liu invest in?
Karen Liu invests primarily in Biotechnology, Health Care and Wellness startups, most often at Series A and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Karen Liu?
Public channels for Karen Liu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Karen Liu last invest?
The most recent investment recorded for Karen Liu closed in Sep 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
